As of its most recent filing, SG Americas Securities LLC has reported an impressive 156.7% increase in its holdings of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) during the fourth quarter. The hedge fund’s latest Form 13F submission to the Securities and Exchange Commission (SEC) shows ownership of 19,501 shares in the healthcare provider after adding another 11,903 shares to its portfolio over the past quarter. This brings SG Americas Securities’ total stake in ACHC to a current value of $1.6 million at the time of reporting.
So what does this mean for investors looking to get involved with this growing healthcare company? Firstly, it could be an indication that SG Americas Securities sees potential in ACHC and is optimistic about its future growth prospects. Hedge funds are known for their keen understanding of market trends and factors that can influence stock values; therefore, if they decide to invest more heavily into a particular company over time, it could mean that they see good things ahead.
Recent trends in ACHC’s stock value have been somewhat fluctuating; however, long-term investors may take solace in the fact that the hedge fund still sees value in the company despite any short-term uncertainties surrounding it. As of April 26th, ACHC’s opening price on NASDAQ stood at $73.78 per share – within touching distance of the firm’s fifty-day moving average price of $73.77 and comfortably below its two-hundred-day moving average price of $79.52.
For those interested in investing in ACHC themselves though – there are several factors worth considering beyond SG Americas’ investment movement alone. While the company does have a debt-to-equity ratio of just .49 and relatively healthy liquidity ratios with both current and quick ratios sitting at around 1.,30 – there is little denying that this is a complex sector undergoing significant transformation.
Looking to other financial reports and filings, Acadia Healthcare Company currently boasts a market cap of around $6.8 billion, a P/E ratio of 24.59 and a P/E/G ratio of 1.57 – suggesting that some investors see it as a reasonable-value growth stock. Yet while our knowledge about the healthcare industry at large and the role ACHC may play in its future continues to evolve, one thing is clear: SG Americas Securities LLC has demonstrated a positive outlook for this growing company that others may wish to continue exploring.
Acadia Healthcare: Mixed reactions from notable investors and research firms
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) recently witnessed some significant moves from notable investors in the fourth quarter of 2022. Oliver Luxxe Assets LLC raised its position in shares of Acadia Healthcare by 2.7%, owning a total of 10,810 shares worth $890,000 after acquiring an additional 284 shares during the period. Robeco Institutional Asset Management B.V., Great West Life Assurance Co. Can, Mount Yale Investment Advisors LLC, and Frontier Capital Management Co. LLC also acquired new positions or raised their existing ones during the period.
Despite these positive moves from notable investors, a number of research firms have expressed concerns over Acadia Healthcare’s performance in recent months. Deutsche Bank Aktiengesellschaft downgraded the stock from “hold” to “sell,” while lowering their target price from $75 to $63 per share. Mizuho also cut their target price on shares of Acadia Healthcare from $87 to $80 and gave it a “neutral” rating for the company. StockNews.com started coverage on the stock with a “hold” rating, while Cantor Fitzgerald started coverage with a “neutral” rating and a $83 price objective. Finally, Stephens dropped their price objective on shares of Acadia Healthcare from $92 to $88 per share and maintained an “equal weight” rating for the company.
Acadia Healthcare engages in the provision of behavioral healthcare services through its United States (U.S.) Facilities and United Kingdom (U.K.) Facilities segments. The U.S facilities segment encompasses acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and outpatient community-based services.
While weighing both positive and negative evaluations surrounding Acadia Healthcare’s financial performance as noted above is important in making an informed decision about investing in this stock; monitoring insider trades and filings on HoldingsChannel.com could provide crucial insights that will aid prospective investors’ analysis better.
Acadia Healthcare reported Q4 2022 earnings data, posting $0.70 EPS for the quarter, missing its estimated consensus of $0.74 by ($0.04). Despite this, the company managed to generate $675.30 million in revenue during the quarter as opposed to predicted estimates that indicated only $659.17 million would be achieved. Acadia Healthcare had a return on equity of 10.19% and a net margin of 10.46%. Analysts are predicting that Acadia Healthcare Company, Inc will post 3.3 EPS for the current year.
In conclusion, investors must conduct careful evaluations taking into consideration significant moves from notable investors such as those seen with Oliver Luxxe Assets LLC, Robeco Institutional Asset Management B.V., Great West Life Assurance Co., Mt Yale Investment Advisors LLC, Frontier Capital Management Co., and institutional investors which make up 99.79% of total stock ownership; alongside trading information via Holdings Channel.com and both positive and negative ratings analysis when considering investment opportunities in ACHC shares.
